Irvine Scientific, a world leader in the development and manufacture of cell culture media, has announced the expansion of its Orange County (California, USA) offices and laboratories, with the addition of a 40,000 square foot purpose-built R&D center at 17112 Armstrong Ave, Irvine, California.
The growth of the company is in response to increased customer demand for Irvine Scientific’s cell culture and media reagents, and follows the significant expansion of its R&D facilities less than 5 years ago.
The new building will also contain other departments that currently reside within its southern California based headquarters enabling the company to expand other capabilities, such as media customization for customers, conducted at its headquarters in Santa Ana.
Along with the other facilities in Santa Ana, CA this increases the total space occupied by Irvine Scientific in Orange County to over 140,000 square feet.
“This addition allows us to continue our expansion of R&D, which supports our longer-term strategy of maintaining a leadership position of innovation in cell culture media and reagents,” said Tim Mullane, Chief Operating Officer.
“Additional capacity will allow us to expand our space and staff dedicated to advancing cell culture technology important to our customers. Along with this growth we will continue to advance our analytical capabilities and services to our customers.”
Customers producing biologicals, vaccines and cell-based therapies often require expert assistance from the company’s scientists and experts to modify and optimise the cell culture conditions during various stages of a programme’s development.
With the opening of the new facility, Irvine Scientific plans to expand the laboratories and staff located in its main Headquarters that are dedicated to providing these services to customers.
Tim Mullane added: “While the R&D capability expands, the space dedicated to our Express Media Services within our corporate HQ location will expand. This group currently supports our biopharmaceutical and cell therapy customers and has experienced dramatic growth in the last several years.”
As the company continues to grow, it intends to continue to expand its offering products and services to biopharmaceutical, stem and immune cell therapy companies and medical devices for the IVF laboratories worldwide.